Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites

doi:10.1016/0197-4580(94)90139-2

Neurobiology of Aging

Volume 15, Issue 1, January–February 1994, Pages 1-9

https://doi.org/10.1016/0197-4580(94)90139-2 Get rights and content

Abstract

We probed serial and near serial sections of cerebellum from 13 Alzheimer's disease (AD), 10 older Down's syndrome (DS) patients, and 9 age-matched, non-AD controls, using single and double labeling immunohistochemistry to investigate the pathologic consequences of β-amyloid or A4 (Aβ) deposits in cerebellum and their relationship to Purkinje cells (PCs). Our data showed that Aβ deposits in cerebellum of AD and older DS adults only form diffuse or preamyloid plaques and the density of Aβ lesions per unit area of molecular layer correlated with the number of PCs per unit length of the subjacent PC layer in double immunostained sections (r = 0.85; p < 0.001). About 65% of these cerebellar Aβ deposits were in physical contact with PC dendrites. No Aβ plaques were found in the cerebellum of controls. Despite the abundance of Aβ deposits in the cerebellar cortex of AD and older DS patients, neither PC bodies nor PC dendrites in physical contact with Aβ lesions showed evidence of structural abnormalities.

References (66)

H. Braak et al.
Alzheimer's disease: Amyloid plaques in the cerebellum
J. Neurol. Sci.
(1989)
G.T. Bramblett et al.
The abnormal phosphorylation of tau at ser396 in Alzheimer's disease recapitulates phosphorylation during development and contributes to reduced microtubule binding
Neuron
(1993)
J.A. Clemens et al.
Implants containing β-amyloid protein are not neurotoxic to young and oldrat brain
Neurobiol. Aging
(1992)
D. Games et al.
Lack of Alzheimer pathology after β-amyloid protein injections in rat brain
Neurobiol. Aging
(1992)
G. Giaccone et al.
Down's Syndrome patients: Extracellular preamyloid deposits precede neuritic degeneration and senile plaques
Neurosci. Lett.
(1989)
G.G. Glenner et al.
Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
Biochem. Biophys. Res. Commun.
(1984)
T.E. Golde et al.
Expression of β amyloid protein precursor mRNAs: Recognition of a novel alternatively spliced form and quantification in Alzheimer's disease using PCR
Neuron
(1990)
J. Hardy et al.
Amyloid deposition as the central event in the aetiology of Alzheimer's disease
Trends Pharmacol Sci
(1991)
J. Kang et al.
Differential splicing of Alzheimer's disease amyloid β/A4 precursor RNA in rat tissues: Preβ/A4(695) mRNA is predominantly produced in rat and human brain
Biochem. Biophys. Res. Commun.
(1990)
K.S. Kosik et al.
Epitopes that span the tau molecular are shared with paired helical filament
Neuron
(1988)

N.W. Kowall et al.

In vivo neurotoxicity of beta amyloid [β(140)] and the β(25–35) fragment

Neurobiol. Aging

(1992)

D.M.A. Mann et al.

The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome

J. Neurol. Sci.

(1989)

P.R. Solomon et al.

Disruption of classical conditioning in patients with Alzheimer's disease

Neurobiol. Aging

(1991)

B. Wiedenmann et al.

Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38000 characteristic of presynaptic vesicles

Cell

(1985)

H. Arai et al.

Defined neurofilament, tau, and β-amyloid precursor protein epitopes distinguish Alzheimer from nonAlzheimer senile plaques

H. Arai et al.

Expression patterns of β-amyloid precursor protein (β-APP) in neural and noneural tissues from Alzheimer's disease and control subjects

Ann. Neurol.

(1991)

H. Arai et al.

Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease

Neurology

(1992)

S. Bahmanyar et al.

Localization of amyloid β protein messenger RNA in brains from patients with Alzheimer's disease

Science

(1987)

E.A. Clark et al.

Characterization and differential distribution of the three major human protein kinase C (PKC) isozymes (PKC alpha, PKC beta, PKC gamma) of the central nervous system in normal and Alzheimer's disease brains

Lab. Invest.

(1991)

M.L. Cohen et al.

In situ hybridization of nucleus basalis neurons shows increased β amyloid mRNA in Alzheimer disease

D.W. Dickson et al.

Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease

Acta Neuropathol.

(1990)

M. Emre et al.

The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected β-amyloid in the rat brain

Neurobiol. Aging

(1992)

M. Gearing et al.

Amyloid precursor protein (APP) in the striatum in Alzheimer's disease: An immunohistochemical study

J. Neuropathol. Exp. Neurol.

(1993)

S.G. Greenberg et al.

A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis

C. Haass et al.

Amyloid β-peptide is produced by cultured cells during normal metabolism

Nature

(1992)

G.A. Higgins et al.

Differential regulation of amyloid β protein mRNA expression within hippocampal neuronal subpopulations in Alzheimer disease

S.-M. Hsu et al.

Color modification of Diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry

J. Histochem. Cytochem.

(1982)

B.T. Hyman et al.

Alzheimer-type pathologic changes in Down's syndrome individuals of various ages

B.T. Hyman et al.

Kunitz protease inhibitor-containing amyloid β protein precursor immunoreactivity in Alzheimer's disease

J. Neuropath. Exp. Neurol.

(1992)

S.I. Ikeda et al.

The morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases: An immunohistochemical study using amyloid beta-protein antibody

Lab. Invest.

(1989)

C.L. Joachim et al.

Diffuse senile plaques occur commonly in the cerebellum of Alzheimer's disease

Am. J. Pathol.

(1989)

C.L. Joachim et al.

The seminal role of β-amyloid in the pathogenesis of Alzheimer disease

Alzheimer Disease and Associated Disorders

(1992)

Z.S. Khachaturian

Diagnosis of Alzheimer's disease

Arch. Neurol.

(1985)

Cited by (71)

Altered microglia and neurovasculature in the Alzheimer's disease cerebellum
2019, Neurobiology of Disease
Citation Excerpt :
These findings provide evidence that AD-related molecular changes occur within non-neuronal cells of the neocerebellum, which may contribute to the symptomatology and pathophysiology of AD. Our study of neocerebellar neuropathology using TMAs revealed a considerable increase in amyloid-β expression and load within AD cases, which is in general agreement with earlier studies of AD neuropathology (Braak et al., 1989; Joachim et al., 1989; Dickson et al., 1990; Li et al., 1994; Fukutani et al., 1997; Wegiel et al., 1999; Wang et al., 2002). Furthermore, no tau-positive neurofibrillary tangles were identified in AD neocerebellar TMA cores, which is in line with previous observations (Joachim et al., 1989; Li et al., 1994; Wegiel et al., 1999; Yamamoto and Hirano, 1985).
Traditionally regarded to coordinate movement, the cerebellum also exerts non-motor functions including the regulation of cognitive and behavioral processing, suggesting a potential role in neurodegenerative conditions affecting cognition, such as Alzheimer's disease (AD). This study aims to investigate neuropathology and AD-related molecular changes within the neocerebellum using post-mortem human brain tissue microarrays (TMAs).
Immunohistochemistry was conducted on neocerebellar paraffin-embedded TMAs from 24 AD and 24 matched control cases, and free-floating neocerebellar sections from 6 AD and 6 controls. Immunoreactivity was compared between control and AD groups for neuropathological hallmarks (amyloid-β, tau, ubiquitin), Purkinje cells (calbindin), microglia (IBA1, HLA-DR), astrocytes (GFAP) basement-membrane associated molecules (fibronectin, collagen IV), endothelial cells (CD31/PECAM-1) and mural cells (PDGFRβ, αSMA).
Amyloid-β expression (total immunolabel intensity) and load (area of immunolabel) was increased by >4-fold within the AD cerebellum. Purkinje cell counts, ubiquitin and tau immunoreactivity were unchanged in AD. IBA1 expression and load was increased by 91% and 69%, respectively, in AD, with no change in IBA1-positive cell number. IBA1-positive cell process length and branching was reduced by 22% and 41%, respectively, in AD. HLA-DR and GFAP immunoreactivity was unchanged in AD. HLA-DR-positive cell process length and branching was reduced by 33% and 49%, respectively, in AD. Fibronectin expression was increased by 27% in AD. Collagen IV, PDGFRβ and αSMA immunoreactivity was unchanged in AD. The number of CD31-positive vessels was increased by 98% in AD, suggesting the increase in CD31 expression and load in AD is due to greater vessel number. The PDGFRβ/CD31 load ratio was reduced by 59% in AD.
These findings provide evidence of molecular changes affecting microglia and the neurovasculature within the AD neocerebellum. These changes, occurring without overt neuropathology, support the hypothesis of microglial and neurovascular dysfunction as drivers of AD, which has implications on the neocerebellar contribution to AD symptomatology and pathophysiology.
Accumulation of amyloid-β in the cerebellar cortex of essential tremor patients
2015, Neurobiology of Disease
Citation Excerpt :
The concept of Aβ accumulation in the cerebellum is not new. By the use of microscopic, biochemical or mass spectrometry approaches, significant levels of Aβ have been reported in the cerebellum of subject with Down's syndrome or AD, typically with an higher incidence in patients with an early onset diagnosis and longer disease duration (Braak et al., 1989; Cole et al., 1989, 1993; Joachim et al., 1989; Yamaguchi et al., 1989; Mann et al., 1990, 1996; Jellinger, 1993; Li et al., 1994; Tamaoka et al., 1995; Lemere et al., 1996; Mann and Iwatsubo, 1996; Fukutani et al., 1997; Wang et al., 2002; Verdile et al., 2004; Portelius et al., 2010; Sepulveda-Falla et al., 2011; Rohn et al., 2013). Here we corroborated the cerebellar Aβ accumulation observed in these studies using samples from our cohort of neuropathologically diagnosed AD patients.
The accumulation of insoluble amyloid-beta (Aβ) peptides is associated with neurodegenerative disorders, such as Alzheimer's disease (AD). As essential tremor (ET) could involve neurodegenerative processes in the cerebellum, we quantified soluble and insoluble Aβ in cerebellar cortices from patients diagnosed with ET (n = 9), compared to Controls (n = 16) or individuals with Parkinson's disease (n = 10). Although ante-mortem cognitive performance was not documented, all individuals included had the diagnosis of AD ruled out by a neuropathologist. ELISA-determined concentrations of insoluble Aβ42 in ET patients displayed a bimodal distribution, with a median 246-fold higher than in Controls (P < 0.01, Kruskal–Wallis). Higher Aβ42 concentrations were measured in the parietal cortex of the same ET patients, compared to Controls (107-fold median increase, P < 0.01, Kruskal–Wallis), but similar phosphorylated tau levels were detected. The rise in cerebellar insoluble Aβ42 concentrations is not associated to APP expression and processing or the ApoE4 status. However, Aβ42 levels in ET individuals were correlated with cerebellar insoluble phosphorylated tau (r² = 0.71, P = 0.005), unphosphorylated neurofilament heavy chain (NF-H; r² = 0.50, P = 0.030) and Lingo-1 (r² = 0.73, P = 0.007), indicative of a generalized neurodegenerative process involving the cerebellum. Our results suggest prevalent accumulations of insoluble Aβ42 in the cerebellum of ET, but not in age-matched PD. Whether this anomaly plays a role in ET symptoms warrants further investigations.
Differential effect of amyloid beta on the cytochrome P450 epoxygenase activity in rat brain
2011, Neuroscience
One of the prominent features of Alzheimer's disease is the excessive accumulation of the protein amyloid beta (Aβ) in certain areas of the brain leading to neurodegeneration. Aβ is cytotoxic and disrupts several cytoprotective pathways. Recent literature has demonstrated that certain cytochrome P450 (CYP) products are neuroprotective, including epoxide metabolites of arachidonic acid (AA), epoxyeicosatrienoic acids (EETs). The action of Aβ with respect to regionally produced EETs in the brain has yet to be defined. Epoxygenases metabolize AA into four regioisomers of EETs (14,15-, 11,12-, 8,9- and 5,6-EET). EETs are rapidly degraded into dihydroxyeicosatrienoic acids (DiHETEs) by soluble epoxide hydrolase (sEH). To determine the effect of Aβ on the epoxygenase activity in different regions of the brain, microsomes were prepared from the cerebrum and cerebellum of adult Sprague–Dawley rats and incubated with 1 and 10 μM Aβ for 30 min after which epoxygenase activity assay was performed. Mass spectrometry indicated that incubation with Aβ reduced 14,15-EET production by 30% as compared to vehicle in the cerebrum, but not in the cerebellum. When we separated the cerebrum into cortex and hippocampus, significant decrease in the production of total EETs and DiHETEs were seen in presence of Aβ (81% and 74%) in the cortex. Moreover, 11,12-EET production was decreased to ∼70% of vehicle in both cortex and hippocampus. Epoxygenase activity in the cultured astrocytes and neurons also showed reduction in total EET and DiHETE production (to 80% and ∼70% of vehicle respectively) in presence of Aβ. Altogether, our data suggest that Aβ reduces epoxygenase activity differentially in a region-specific and cell-specific manner. The reduction of cytoprotective EETs by Aβ in the cerebrum may make it more prone to degeneration than the cerebellum. Further understanding of these interactions will improve our ability to protect against the pathology of Alzheimer's disease.
Isolation and characterization of patient-derived, toxic, high mass Amyloid β-protein (Aβ) assembly from Alzheimer disease brains
2009, Journal of Biological Chemistry
Citation Excerpt :
Furthermore, in AD patients with severe pathology, significantly higher amounts of native ASPD were detected in the frontal or temporal cortices (7.2 ± 1.5 nmol/g brain tissue, n = 3, Scheffé post hoc test p = 0.0012) than in the cerebellum (0.14 ± 0.1 nmol/g brain tissue). The result is consistent with previous findings that the cerebellum in AD is pathologically less affected (44, 45). The above observations suggest the involvement of native ASPDs in neurodegeneration of AD brains.
Amyloid β-protein (Aβ) assemblies are thought to play primary roles in Alzheimer disease (AD). They are considered to acquire surface tertiary structures, not present in physiologic monomers, that are responsible for exerting toxicity, probably through abnormal interactions with their target(s). Therefore, Aβ assemblies having distinct surface tertiary structures should cause neurotoxicity through distinct mechanisms. Aiming to clarify the molecular basis of neuronal loss, which is a central phenotype in neurodegenerative diseases such as AD, we report here the selective immunoisolation of neurotoxic 10–15-nm spherical Aβ assemblies termed native amylospheroids (native ASPDs) from AD and dementia with Lewy bodies brains, using ASPD tertiary structure-dependent antibodies. In AD patients, the amount of native ASPDs was correlated with the pathologic severity of disease. Native ASPDs are anti-pan oligomer A11 antibody-negative, high mass (>100 kDa) assemblies that induce degeneration particularly of mature neurons, including those of human origin, in vitro. Importantly, their immunospecificity strongly suggests that native ASPDs have a distinct surface tertiary structure from other reported assemblies such as dimers, Aβ-derived diffusible ligands, and A11-positive assemblies. Only ASPD tertiary structure-dependent antibodies could block ASPD-induced neurodegeneration. ASPDs bind presynaptic target(s) on mature neurons and have a mode of toxicity different from those of other assemblies, which have been reported to exert their toxicity through binding postsynaptic targets and probably perturbing glutamatergic synaptic transmission. Thus, our findings indicate that native ASPDs with a distinct toxic surface induce neuronal loss through a different mechanism from other Aβ assemblies.
Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease
2009, Alzheimer's and Dementia
Citation Excerpt :
Here we examined the association between PBL and cerebellum telomere lengths in AD, and also compared telomere lengths in the cerebella of AD patients and control subjects. We chose the cerebellum because whereas it may suffer limited pathology in AD, including atrophy of the molecular and granular layers [31], it does not experience gliosis [31–33]. Thus, the measurement of cerebellar telomere length should not be complicated by telomerase expression in proliferating glial cells.
Alzheimer's disease (AD) patients have been reported to have shorter telomeres in peripheral blood leukocytes (PBLs) than age-matched control subjects. However, it is unclear if PBL telomere length reflects brain telomere length, which might play a more direct role in AD pathogenesis. We examined the correlation between PBL and cerebellum telomere length in AD patients, and compared telomere lengths in cerebella from individuals with AD versus age-matched control subjects.
Mean telomere lengths were measured using quantitative telomere polymerase chain reaction of genomic DNA prepared from matched PBL and cerebellum samples from 29 individuals with pathologically confirmed sporadic AD. Telomere length was also measured in cerebellum samples of 30 AD patients versus 22 unaffected age-matched control subjects.
The PBL and cerebellum telomere lengths were directly correlated in individuals with AD (r = 0.42, P = 0.023). Nonetheless, cerebellum telomere lengths were not significantly different in AD patients and age-matched control subjects.
Reduced PBL telomere length in AD might not reflect reduced telomere length in bulk brain tissue, but may be a marker of changes in a subset of brain tissues or other tissues that affect the pathogenesis of AD.
Effects of treadmill exercise on memory and c-Fos expression in the hippocampus of the rats with intracerebroventricular injection of streptozotocin
2008, Neuroscience Letters
Alzheimer's disease is a progressive neurodegenerative disease clinically characterized by dementia and neurobehavioral deterioration. Hippocampal neurons are vulnerable to injury induced by Alzheimer's disease. The immediate early gene c-Fos has been used as a marker of neuronal activity. In the present study, we investigated the effects of treadmill exercise on long-term memory capacity and c-Fos expression in the hippocampus of rats with Alzheimer's disease. The rat model of Alzheimer's disease used in the present study was induced by the intracerebroventricular (ICV) injection of streptozotocin (STZ) using a stereotaxic instrument. The rats in the exercise group were forced to run on a treadmill for 30 min once daily for 14 consecutive days starting at 3 days after the ICV injection of STZ. The results of the present study showed that ICV injection of STZ impaired long-term memory capacity and decreased the number of c-Fos-positive cells in several regions of the rat hippocampus. However, treadmill exercise alleviated long-term memory deficits and enhanced c-Fos expression in the rats with ICV injection of STZ. The results of the present study showed that treadmill exercise could be a useful strategy for treating several neurodegenerative diseases.

View all citing articles on Scopus

View full text

Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites

Abstract

J. Neurol. Sci.

Neuron

Neurobiol. Aging

Neurobiol. Aging

Neurosci. Lett.

Biochem. Biophys. Res. Commun.

Neuron

Trends Pharmacol Sci

Biochem. Biophys. Res. Commun.

Neuron

Neurobiol. Aging

J. Neurol. Sci.

Neurobiol. Aging

Cell

Defined neurofilament, tau, and β-amyloid precursor protein epitopes distinguish Alzheimer from nonAlzheimer senile plaques

Expression patterns of β-amyloid precursor protein (β-APP) in neural and noneural tissues from Alzheimer's disease and control subjects

Ann. Neurol.

Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease

Neurology

Localization of amyloid β protein messenger RNA in brains from patients with Alzheimer's disease

Science

Characterization and differential distribution of the three major human protein kinase C (PKC) isozymes (PKC alpha, PKC beta, PKC gamma) of the central nervous system in normal and Alzheimer's disease brains

Lab. Invest.

In situ hybridization of nucleus basalis neurons shows increased β amyloid mRNA in Alzheimer disease

Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease

Acta Neuropathol.

The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected β-amyloid in the rat brain

Neurobiol. Aging

Amyloid precursor protein (APP) in the striatum in Alzheimer's disease: An immunohistochemical study

J. Neuropathol. Exp. Neurol.

A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis

Amyloid β-peptide is produced by cultured cells during normal metabolism

Nature

Differential regulation of amyloid β protein mRNA expression within hippocampal neuronal subpopulations in Alzheimer disease

Color modification of Diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry

J. Histochem. Cytochem.

Alzheimer-type pathologic changes in Down's syndrome individuals of various ages

Kunitz protease inhibitor-containing amyloid β protein precursor immunoreactivity in Alzheimer's disease

J. Neuropath. Exp. Neurol.

The morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases: An immunohistochemical study using amyloid beta-protein antibody

Lab. Invest.

Diffuse senile plaques occur commonly in the cerebellum of Alzheimer's disease

Am. J. Pathol.

The seminal role of β-amyloid in the pathogenesis of Alzheimer disease

Alzheimer Disease and Associated Disorders

Diagnosis of Alzheimer's disease

Arch. Neurol.